Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia, 2002; 43(Suppl 3):53-9. https://doi.org/10.1046/j.1528-1157.43.s.3.5.x |
|
Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol, 2008; 48:303-32. https://doi.org/10.1146/annurev.pharmtox.48.113006.094708 |
|
Auby P. Pharmaceutical research in pediatric populations and the new EU Pediatric Legislation: an industry perspective. Child Adolesc Psychiatry Mental Health, 2008; 2:38. https://doi.org/10.1186/1753-2000-2-38 |
|
Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet, 2006; 45(11):1077-97. https://doi.org/10.2165/00003088-200645110-00003 |
|
Breitkreutz J. European perspectives on pediatric formulations. Clin Ther, 2008; 30:2146-54. https://doi.org/10.1016/j.clinthera.2008.11.016 |
|
Blum MR, Liao SH, Good SS, De Miranda P. Pharmacokinetic and bioavailability of zidovudine in humans. Am J Med, 1988; 85: 189-94. |
|
Bureau, U. S. C. (2021, October 8). National population by characteristics: 2010-2020. Census.gov. Available via https://www.census. gov/programssurveys/popest/technical-documentation/research/evaluationestimates/2020-evaluationestimates/2010s-national-detail.html (Accessed 16 May 2022). |
|
Caparelli EV, Williams PJ. Pharmacometrics in pharmacotherapy and drug development: pediatric application. In: Ette EI, William PJ (eds.). Pharmacometrics: the science of quantitative pharmacology, John Willey & Sons, Inc., Hoboken, NY, 2007. |
|
Cella M, Knibbe C, Danhof M, Della PO. What is the right dose for children? Br J Clin Pharmacol, 2012; 70:597-603. https://doi.org/10.1111/j.1365-2125.2009.03591.x |
|
Chokephaibulkit K, Cressey TR, Capparelli E, Sirisanthana V, Muresan P, Hongsiriwon S, Ngampiyaskul C, Limwongse C, Wittawatmongkol O, Aurpibul L, Kabat B, Toye M, Smith ME, Eksaengsri A, McIntosh K, Yogev R, Team IP. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antiviral Ther, 2011; 16(8):1287-95. https://doi.org/10.3851/IMP1931 |
|
DHHS. Department of Health and Human Services, guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. US FDA, Rockfville, MD, 1998. |
|
Esseku F, Joshi A, Oyegbile Y, Edowhorhu G, Gbadero D, Adeyeye M. A randomized pahse I bioequivalence clinincal trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers. Antiviral Ther, 2013; 18(2):205-12. https://doi.org/10.3851/IMP2310 |
|
French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D, OzCombo I. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. HIV Clin Trials, 2002; 3(3):177-85. https://doi.org/10.1310/9N21-1HG1-7N1Q-JKW1 |
|
Giacoia GP, Mattison DR. Newborns and drug studies: the NICHD/FDA newborn drug development initiative. Clin Ther, 2005; 27(6):796-813. https://doi.org/10.1016/j.clinthera.2005.06.008 |
|
Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet, 1996; 30:329-32. https://doi.org/10.2165/00003088-199630050-00001 |
|
Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci, 2013; 102:2941-52. https://doi.org/10.1002/jps.23574 |
|
Johnson TN. The problems in scaling adult drug doses to children. Arch Dis Child, 2008; 93:207-11. https://doi.org/10.1136/adc.2006.114835 |
|
Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharm, 2011; 50(5):331-47. https://doi.org/10.2165/11539680-000000000-00000 |
|
Kayitare E, Vervaet C, Ntawukulilyayo JD, Seminega B, Bortel V, Remon JP. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. Int J Pharm, 2009; 370(1-2):41-6. https://doi.org/10.1016/j.ijpharm.2008.11.005 |
|
Leeder JS, Keaarns GL, Spielberg, SP Anker JV. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol, 2010; 50(12):1377-87. https://doi.org/10.1177/0091270009360533 |
|
Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol, 2006; 61:545-57. https://doi.org/10.1111/j.1365-2125.2006.02622.x |
|
Marier JF, Dimarco M, Guilbaud R, Dodard C, Morelli G, Tippabhotla SK, Singla AK, Thudi NR, Monif T. Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. J Clin Pharmacol, 2007; 47(11):1381-9. https://doi.org/10.1177/0091270007307572 |
|
Moffat AC, Osselton MD, Widdop B, Watts. Clarke's analysis of drugs and poisons: In: Pharmaceuticals, body fluids and postmortem material. Pharmaceutical Press, London, UK, 2011. |
|
Monif T, Reyar S, Tiwari HK, Tippabhotla SK, Khuroo A, Thudi NR, Ahmed S, Raghuvanshi R. A single-dose, randomized, open-label, twoperiod crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers. Arzneimittelforschung, 2009; 59(2):104-8. https://doi.org/10.1055/s-0031-1296371 |
|
Otukesh H, Hoseini R, Rahimzadeh N, Hosseini S. Glomerular function in neonates. Br J Clin Pharmacol, 2012; 40(5):439-43. |
|
Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, Mane AA, Bhagat S. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr, 2004; 37(5):1566-9. https://doi.org/10.1097/00126334-200412150-00005 |
|
Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J. Disposition and biotransformation of antiretroviral drug nevirapine in humans. Drug Metab Dispos, 1990; 27:895-901. |
|
Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol, 2011; 51:45-73. https://doi.org/10.1146/annurev-pharmtox-010510-100540 |
|
Sabo JP, Lamson MJ, Leitz G, Yong C, MacGregor TR. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS Pharm Sci, 2002; 2:1-9. https://doi.org/10.1208/ps020101 |
|
Todd M, Jullien V, Pons G. Facilitation of drug evaluationin children by population methods and modeling. Clin Pharmacokinet, 2008; 47:231-43.
https://doi.org/10.2165/00003088-200847040-00002 |
|
Trivedi A, Lee RE, Meibohm B. Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives [Internet]. Expert Rev Clin Pharmacol, 2013; 6. Available via http://www.ncbi.nlm.nih. gov/pmc/articles/PMC3809903/ (Accessed 22 December 2015). https://doi.org/10.1586/ecp.13.6 |
|
U.S. Census Bureau. USAGov. (n.d.). Available via https://www. usa.gov/federal-agencies/u-s-census-bureau (Accessed 16 May 2022). |
|
Van der Heijden AJ, Grose WF, Ambagtsheer JJ, Provoost AP, Wolff ED, Sauer PJ. Glomerular filtration rate in the preterm infant: the relation to gestational and postnatal age. Eur J Pediatr, 1988; 148:24-8. https://doi.org/10.1007/BF00441807 |
|
VanLeeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase 1 study. AIDS, 1992; 6:1471-5. https://doi.org/10.1097/00002030-199212000-00008 |
|
Ziswoski J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics, 2010; 2:364-88. https://doi.org/10.3390/pharmaceutics2040364 |